Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7319)
All Articles published online
|
Publishing Process of This Article
|
Aug 10, 2015 (publication date) through Feb 15, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Shameem R, Hamid MS, Xu KY, Wu S. Comparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with metastatic castration-resistant prostate cancer. World J Clin Oncol 2015; 6(4): 64-72 [PMID: 26266103 DOI: 10.5306/wjco.v6.i4.64] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v6/i4/64.htm |
| Number | Citing Articles |
| 1 |
Haofeng Zheng, Jialiang Chen, Wenhan Qiu, Sijie Lin, Yanxiong Chen, Guancan Liang, Youqiang Fang. Safety and Efficacy of First-Line Treatments for Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Indirect Comparison. BioMed Research International 2017; 2017: 1 doi: 10.1155/2017/3941217
|
| 2 |
M. Koninckx, J. L. Marco, I. Pérez, M. T. Faus, V. Alcolea, F. Gómez. Effectiveness, safety and cost of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world data analysis. Clinical and Translational Oncology 2019; 21(3): 314 doi: 10.1007/s12094-018-1921-5
|
| 3 |
Chengkuan Cai, Jingyuan Tang, Baixin Shen, Liucheng Ding, Yunpeng Shao, Zhengsen Chen, Yinchao Ma, Haoliang Xue, Zhongqing Wei. Preclinical trial of the multi-targeted lenvatinib in combination with cellular immunotherapy for treatment of renal cell carcinoma. Experimental and Therapeutic Medicine 2017; 14(4): 3221 doi: 10.3892/etm.2017.4858
|
| 4 |
Seung-hwan Jeong, Sang Eun Yeon, Su Youn Kim, Tae Gyun Kwon, Seong Soo Jeon, Young Deuk Choi, Dongdeuk Kwon, Byung Ha Chung, Sung-Hoo Hong, Byung Hoon Kim, Hyo Jin Lee, Sang Joon Shin, Woo Suk Choi, Sung Woo Park, Taek Won Kang, Seok Joong Yun, Jin Seon Cho, See Min Choi, Na-Ri Lee, Cheol Kwak. A prospective, multicenter study on the clinical effectiveness of abiraterone in metastatic castration-resistant prostate cancer in Korea: Pre- vs. post-chemotherapy. Investigative and Clinical Urology 2023; 64(5): 466 doi: 10.4111/icu.20230128
|
| 5 |
Kapil Dev Mehta. Abiraterone: A Review of its Pharmacokinetic, Pharmacodynamic Profile and Clinical Efficacy. Urology & Nephrology Open Access Journal 2016; 3(3) doi: 10.15406/unoaj.2016.03.00079
|
| 6 |
Sabin Goktas Aydin, Yasin Kutlu, Harun Muglu, Ahmet Aydin, Ozgur Acikgoz, Jamshid Hamdard, Ebru Karci, Ahmet Bilici, Omer Fatih Olmez, Ozcan Yildiz. Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide. Cancer Chemotherapy and Pharmacology 2024; 93(1): 71 doi: 10.1007/s00280-023-04592-x
|
| 7 |
Rahma Said, Javier Hernández‐Losa, Amine Derouiche, Teresa Moline, Rosa Somoza Lopez de Haro, Skander Zouari, Ahlem Blel, Soumaya Rammeh, Slah Ouerhani. Correlation between E‐cadherin/β‐catenin, Vimentin expression, clinicopathologic features and drug resistance prediction in naïve prostate cancer: A molecular and clinical study. genesis 2024; 62(1) doi: 10.1002/dvg.23543
|
| 8 |
Bin Zhang, Feng Tao, Hao Zhang. Metastasis-associated protein 2 promotes the metastasis of non-small cell lung carcinoma by regulating the ERK/AKT and VEGF signaling pathways. Molecular Medicine Reports 2018; doi: 10.3892/mmr.2018.8535
|
| 9 |
George Liamis, Theodosios D. Filippatos, Moses S. Elisaf. Electrolyte disorders associated with the use of anticancer drugs. European Journal of Pharmacology 2016; 777: 78 doi: 10.1016/j.ejphar.2016.02.064
|